跳至主要内容
临床试验/NL-OMON31511
NL-OMON31511已完成4 期

Ribavirin: its dosing regime - Ribados

niversiteit Maastricht0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • According to standard treatment of HCV with ribavirin. Additional for this study:
  • -Obtained written informed consent
  • -Age above 18 years
  • -Body weight >=70 kg: At a lower body weight, a dose of ribavirin is used (400/600mg a day) that cannot be used in this study.;Main inclusion criteria for standard treatment are:
  • Anti-HCV positivity >6 months
  • Positive HCV-RNA genotype 1 or 4
  • Liver biopsy within one year before start of treatment
  • intention to be treated and participate treatment

排除标准

  • Main exclusioncriteria for the standard treatment are:
  • Pregnancy or intention to get pregnant within the treatment period + 6 months
  • no adequate contraception (for men and women)
  • HIV positivity
  • Active uncontrolled psychiatric disorders and suicidal leanings
  • patients with a history of uncontrolled seizure or other significant CNS dysfunction
  • Chemotherapy, systemic antiviral treatment during 6 months prior to study entry
  • Other serious disease

研究者

相似试验